Michael L. Hancock

7.8k total citations · 1 hit paper
65 papers, 5.6k citations indexed

About

Michael L. Hancock is a scholar working on Public Health, Environmental and Occupational Health, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Michael L. Hancock has authored 65 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Public Health, Environmental and Occupational Health, 23 papers in Pulmonary and Respiratory Medicine and 19 papers in Oncology. Recurrent topics in Michael L. Hancock's work include Acute Lymphoblastic Leukemia research (28 papers), Prostate Cancer Treatment and Research (16 papers) and Childhood Cancer Survivors' Quality of Life (13 papers). Michael L. Hancock is often cited by papers focused on Acute Lymphoblastic Leukemia research (28 papers), Prostate Cancer Treatment and Research (16 papers) and Childhood Cancer Survivors' Quality of Life (13 papers). Michael L. Hancock collaborates with scholars based in United States, Australia and Hungary. Michael L. Hancock's co-authors include Ching‐Hon Pui, Gaston K. Rivera, William E. Evans, James M. Boyett, John T. Sandlund, Raul C. Ribeiro, Frederick G. Behm, Mary V. Relling, Jeffrey E. Rubnitz and Mitchell S. Steiner and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Michael L. Hancock

64 papers receiving 5.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Acute Myeloid Leukemia in Children Treated with Epipodophyllotoxins for Acute Lymphoblastic Leukemia

1991 523 citations Ching‐Hon Pui, Raul C. Ribeiro et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael L. Hancock United States	33	2.4k	1.7k	1.6k	1.2k	1.2k	65	5.6k
Wenjian Yang United States	38	2.5k 1.0×	1.9k 1.1×	1.0k 0.6×	913 0.7×	1.9k 1.6×	114	5.5k
John T. Sandlund United States	60	5.8k 2.4×	4.0k 2.4×	3.4k 2.1×	2.3k 1.8×	1.7k 1.5×	169	10.5k
Manuel Praga Spain	51	710 0.3×	865 0.5×	855 0.5×	330 0.3×	1.8k 1.6×	330	10.7k
Kristine R. Crews United States	38	1.5k 0.6×	1.7k 1.0×	622 0.4×	920 0.7×	1.2k 1.0×	100	4.9k
Maarten Naesens Belgium	55	1.2k 0.5×	1.3k 0.8×	248 0.2×	972 0.8×	1.1k 1.0×	242	9.0k
Fernando G. Cosio United States	53	1.4k 0.6×	475 0.3×	595 0.4×	365 0.3×	1.2k 1.0×	143	9.4k
R. Donald Harvey United States	36	625 0.3×	300 0.2×	1.1k 0.7×	1.8k 1.4×	1.9k 1.7×	167	4.8k
Kim Solez United States	45	1.2k 0.5×	566 0.3×	208 0.1×	502 0.4×	854 0.7×	179	8.5k
Éric Thervet France	38	541 0.2×	583 0.4×	384 0.2×	378 0.3×	766 0.7×	143	4.9k
James L. Wade United States	45	450 0.2×	344 0.2×	1.2k 0.7×	4.3k 3.5×	1.3k 1.1×	153	7.6k

Countries citing papers authored by Michael L. Hancock

Since Specialization

Citations

This map shows the geographic impact of Michael L. Hancock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael L. Hancock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael L. Hancock more than expected).

Fields of papers citing papers by Michael L. Hancock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael L. Hancock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael L. Hancock. The network helps show where Michael L. Hancock may publish in the future.

Co-authorship network of co-authors of Michael L. Hancock

This figure shows the co-authorship network connecting the top 25 collaborators of Michael L. Hancock. A scholar is included among the top collaborators of Michael L. Hancock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael L. Hancock. Michael L. Hancock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rosenbloom, Michael, et al.. (2018). Asanguinous Del Nido Cardioplegia for an Aortic Valve Replacement Patient with Cold Agglutinins. Journal of ExtraCorporeal Technology. 50(3). 187–188. 2 indexed citations

Bock, Martin de, Julie Dart, Michael L. Hancock, et al.. (2018). Performance of Medtronic Hybrid Closed-Loop Iterations: Results from a Randomized Trial in Adolescents with Type 1 Diabetes. Diabetes Technology & Therapeutics. 20(10). 693–697. 18 indexed citations

Crawford, Jeffrey, Carla M. Prado, Mary Ann Johnston, et al.. (2016). Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials). Current Oncology Reports. 18(6). 37–37. 128 indexed citations

Yu, Evan Y., Robert H. Getzenberg, Christopher C. Coss, et al.. (2014). Selective Estrogen Receptor Alpha Agonist GTx-758 Decreases Testosterone with Reduced Side Effects of Androgen Deprivation Therapy in Men with Advanced Prostate Cancer. European Urology. 67(2). 334–341. 16 indexed citations

Dobs, Adrian S., Ralph V. Boccia, Nashat Gabrail, et al.. (2013). Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. The Lancet Oncology. 14(4). 335–345. 279 indexed citations

Williams, Ruth, et al.. (2007). Establishing the Use of Body Mass Index as an Indicator of Nutrition Risk in Children With Cancer. Journal of Parenteral and Enteral Nutrition. 31(1). 53–57. 15 indexed citations

Pollack, Ian F., Regina I. Jakacki, Susan M. Blaney, et al.. (2007). Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: A Pediatric Brain Tumor Consortium report1. Neuro-Oncology. 9(2). 145–160. 132 indexed citations

Hoffer, Fredric A., et al.. (2007). Pleurodesis for effusions in pediatric oncology patients at end of life. Pediatric Radiology. 37(3). 269–273. 16 indexed citations

Rivera, Gaston K., Yinmei Zhou, Michael L. Hancock, et al.. (2004). Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia. Cancer. 103(2). 368–376. 64 indexed citations

10.

Lowe, Eric, Ching‐Hon Pui, Michael L. Hancock, et al.. (2004). Early complications in children with acute lymphoblastic leukemia presenting with hyperleukocytosis. Pediatric Blood & Cancer. 45(1). 10–15. 71 indexed citations

11.

Lamba, Vishal, Jatinder K. Lamba, Kazuto Yasuda, et al.. (2003). Hepatic CYP2B6 Expression: Gender and Ethnic Differences and Relationship to CYP2B6 Genotype and CAR (Constitutive Androstane Receptor) Expression. Journal of Pharmacology and Experimental Therapeutics. 307(3). 906–922. 320 indexed citations

12.

Metzger, Monika L., Scott C. Howard, Ligia Fú, et al.. (2003). Outcome of childhood acute lymphoblastic leukaemia in resource-poor countries. The Lancet. 362(9385). 706–708. 136 indexed citations

13.

Blanco, Javier G., Mathew J. Edick, Michael L. Hancock, et al.. (2002). Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics. 12(8). 605–611. 77 indexed citations

14.

Zhang, Jiong, Peter Kuehl, E D Green, et al.. (2001). The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics. 11(7). 555–572. 246 indexed citations

15.

Relling, Mary V., Jeffrey E. Rubnitz, Gaston K. Rivera, et al.. (1999). High incidence of secondary brain tumours after radiotherapy and antimetabolites. The Lancet. 354(9172). 34–39. 288 indexed citations

16.

Coustan‐Smith, Elaine, Frederick G. Behm, Joaquín Sánchez, et al.. (1998). Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. The Lancet. 351(9102). 550–554. 329 indexed citations

17.

Pui, Ching‐Hon, James M. Boyett, Walter T. Hughes, et al.. (1997). Human Granulocyte Colony-Stimulating Factor after Induction Chemotherapy in Children with Acute Lymphoblastic Leukemia. New England Journal of Medicine. 336(25). 1781–1787. 122 indexed citations

18.

Rivera, Gaston K., Ching-Hon Pui, Victor M. Santana, et al.. (1993). Progress in the treatment of adolescents with acute lymphoblastic leukemia. Cancer. 71(S10). 3400–3405. 18 indexed citations

19.

Mahmoud, Hazem H., Gaston K. Rivera, Michael L. Hancock, et al.. (1993). Low Leukocyte Counts with Blast Cells in Cerebrospinal Fluid of Children with Newly Diagnosed Acute Lymphoblastic Leukemia. New England Journal of Medicine. 329(5). 314–319. 144 indexed citations

20.

Pui, Ching‐Hon, Raul C. Ribeiro, Michael L. Hancock, et al.. (1991). Acute Myeloid Leukemia in Children Treated with Epipodophyllotoxins for Acute Lymphoblastic Leukemia. New England Journal of Medicine. 325(24). 1682–1687. 523 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact